Galen medical journal · 2025
Evaluating C-peptide Levels in Children with Type 1 Diabetes and Its Association with Anthropometric and Clinical Variables : C-peptide Levels and Clinical Variables in Pediatric T1DM.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sahraian Raha, Amirhakimi Anis, Kamyab Parnia
Аннотация
BACKGROUND: C-peptide, a byproduct of insulin production, plays significant physiological roles, including stabilizing blood glucose levels and protecting tissues. Its potential therapeutic role in Type 1 diabetes mellitus (T1DM) management remains underexplored, particularly in preserving β-cell function and improving glycemic control.
MATERIALS AND METHODS: This cross-sectional study included 69 pediatric patients with T1DM at Bo Ali Diabetes Clinic, Shiraz, Iran, from December 2022 to April 2023. Patients with a disease duration less than 2 years or metabolic comorbidities were excluded. Anthropometric measurements, HbA1c, and serum C-peptide levels were collected after three months of dietary counseling and insulin adjustment. Data were analyzed using Spearman's correlation and linear regression.
RESULTS: The study population consisted of 69 children (mean age: 11.92 ± 3.65 years; mean disease duration: 63.13 ± 33.16 months). Serum C-peptide levels (mean: 87.02 ± 73.89 pmol/L) were inversely correlated with disease duration (ρ=-0.433, P0.001) and HbA1c (ρ=-0.404, P=0.001). Regression analysis confirmed that both HbA1c and disease duration were significant predictors of C-peptide levels (P0.05). However, no significant associations were observed between C-peptide and age, weight, height, or BMI.
CONCLUSION: Reduced C-peptide levels are correlated with poorer glycemic control (greater HbA1c) and longer disease duration in children with T1DM. These findings highlight the clinical relevance of C-peptide supplementation as a potential therapeutic strategy to preserve β-cell function and improve long-term outcomes in T1DM management. Longitudinal studies are warranted to further evaluate its efficacy.
MATERIALS AND METHODS: This cross-sectional study included 69 pediatric patients with T1DM at Bo Ali Diabetes Clinic, Shiraz, Iran, from December 2022 to April 2023. Patients with a disease duration less than 2 years or metabolic comorbidities were excluded. Anthropometric measurements, HbA1c, and serum C-peptide levels were collected after three months of dietary counseling and insulin adjustment. Data were analyzed using Spearman's correlation and linear regression.
RESULTS: The study population consisted of 69 children (mean age: 11.92 ± 3.65 years; mean disease duration: 63.13 ± 33.16 months). Serum C-peptide levels (mean: 87.02 ± 73.89 pmol/L) were inversely correlated with disease duration (ρ=-0.433, P0.001) and HbA1c (ρ=-0.404, P=0.001). Regression analysis confirmed that both HbA1c and disease duration were significant predictors of C-peptide levels (P0.05). However, no significant associations were observed between C-peptide and age, weight, height, or BMI.
CONCLUSION: Reduced C-peptide levels are correlated with poorer glycemic control (greater HbA1c) and longer disease duration in children with T1DM. These findings highlight the clinical relevance of C-peptide supplementation as a potential therapeutic strategy to preserve β-cell function and improve long-term outcomes in T1DM management. Longitudinal studies are warranted to further evaluate its efficacy.